DYRK1A
Dual specificity tyrosine-phosphorylation-regulated kinase 1A
As of the edition of 20 October 2026, DYRK1A (dual specificity tyrosine-phosphorylation-regulated kinase 1A, UniProt Q13627) has 3 drugs tested at it and 2 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13627
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 92
- Disease areas
- Bones, joints and muscles; Hormones; Injuries; Cancer; Digestive system; Nutrition and metabolism
- Registered trials of its drugs
- 19
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lorecivivint | Stopped | Phase 3 | none listed |
| Harmine | Active | Phase 1 | none listed |
| SM04755 | Went quiet | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Biosplice Therapeutics | Route A |
The other 1 company at DYRK1A
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at DYRK1A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.